Kristina Jankovic
@kjankovic.bsky.social
🎀Medical oncology resident, PhD student of medical sciences, ESOncology fellow, OncoAlert AF | 🏩 Oncology clinic, University Clinical Center Nis, Serbia 🇷🇸
#oncology #breastcancer 🎀
#oncology #breastcancer 🎀
Pinned
Kristina Jankovic
@kjankovic.bsky.social
· Jan 10
Dear colleagues,
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈
📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology
Don’t miss this unique #oncology event! 🌍👩⚕️👨⚕️
@oncoalert.bsky.social #OncoAlertAF
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈
📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology
Don’t miss this unique #oncology event! 🌍👩⚕️👨⚕️
@oncoalert.bsky.social #OncoAlertAF
🦴 #BoneHealth in newly diagnosed female #BreastCancer patients in China 🇨🇳
❗ 63.2% have Abnormal Bone Mass
🔺 92.3% with Vitamin D deficiency
⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls
🧑⚕️ Young BC patients (<45) 9x higher risk
@oncoalert.bsky.social @nature.com
👉 nature.com/articles/s41598-024-84698-1
❗ 63.2% have Abnormal Bone Mass
🔺 92.3% with Vitamin D deficiency
⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls
🧑⚕️ Young BC patients (<45) 9x higher risk
@oncoalert.bsky.social @nature.com
👉 nature.com/articles/s41598-024-84698-1
February 2, 2025 at 2:17 PM
🦴 #BoneHealth in newly diagnosed female #BreastCancer patients in China 🇨🇳
❗ 63.2% have Abnormal Bone Mass
🔺 92.3% with Vitamin D deficiency
⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls
🧑⚕️ Young BC patients (<45) 9x higher risk
@oncoalert.bsky.social @nature.com
👉 nature.com/articles/s41598-024-84698-1
❗ 63.2% have Abnormal Bone Mass
🔺 92.3% with Vitamin D deficiency
⚠️ 5.5x ⬆️ risk of ABM in BC 🆚 controls
🧑⚕️ Young BC patients (<45) 9x higher risk
@oncoalert.bsky.social @nature.com
👉 nature.com/articles/s41598-024-84698-1
Urinary DNA methylation test:
✅89% sensitivity for high-grade or invasive #BladderCancer‼️
✅Outperforms NMP22 & urine cytology tests with high specificity
✅Excellent negative predictive value
🔽Suboptimal positive predictive value
@oncoalert.bsky.social
jamanetwork.com/journals/jam...
✅89% sensitivity for high-grade or invasive #BladderCancer‼️
✅Outperforms NMP22 & urine cytology tests with high specificity
✅Excellent negative predictive value
🔽Suboptimal positive predictive value
@oncoalert.bsky.social
jamanetwork.com/journals/jam...
February 2, 2025 at 2:15 PM
Urinary DNA methylation test:
✅89% sensitivity for high-grade or invasive #BladderCancer‼️
✅Outperforms NMP22 & urine cytology tests with high specificity
✅Excellent negative predictive value
🔽Suboptimal positive predictive value
@oncoalert.bsky.social
jamanetwork.com/journals/jam...
✅89% sensitivity for high-grade or invasive #BladderCancer‼️
✅Outperforms NMP22 & urine cytology tests with high specificity
✅Excellent negative predictive value
🔽Suboptimal positive predictive value
@oncoalert.bsky.social
jamanetwork.com/journals/jam...
💫 Phase 3 #KEYNOTE756 trial - 1⃣st interim analysis: 💫
✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social
✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social
January 26, 2025 at 7:16 PM
💫 Phase 3 #KEYNOTE756 trial - 1⃣st interim analysis: 💫
✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social
✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social
Dear Colleagues,
Don’t miss #OncoAlertColloquium & our #BreastCancer Faculty: brilliant dr Matteo Lambertini 🇮🇹, presenting on #FertilityPreservation (year in review) on February 5, 2025.
REGISTER for FREE HERE
👉 buff.ly/3CChgre
@oncoalert.bsky.social
Don’t miss #OncoAlertColloquium & our #BreastCancer Faculty: brilliant dr Matteo Lambertini 🇮🇹, presenting on #FertilityPreservation (year in review) on February 5, 2025.
REGISTER for FREE HERE
👉 buff.ly/3CChgre
@oncoalert.bsky.social
January 23, 2025 at 10:20 PM
Dear Colleagues,
Don’t miss #OncoAlertColloquium & our #BreastCancer Faculty: brilliant dr Matteo Lambertini 🇮🇹, presenting on #FertilityPreservation (year in review) on February 5, 2025.
REGISTER for FREE HERE
👉 buff.ly/3CChgre
@oncoalert.bsky.social
Don’t miss #OncoAlertColloquium & our #BreastCancer Faculty: brilliant dr Matteo Lambertini 🇮🇹, presenting on #FertilityPreservation (year in review) on February 5, 2025.
REGISTER for FREE HERE
👉 buff.ly/3CChgre
@oncoalert.bsky.social
This article explores the social, psychological & cognitive factors contributing to overtreatment at the #EOL and strategies to address them. @oncoalert.bsky.social
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
#PallOnc discussion @pallonccop.bsky.social
Why does #overtreatment happen in #oncology?
This article defines the #bias and #heuristic that leads to excessive 🔪☢️💉
Solution? #SuppOnc skills - Delivering #BadNews, compassionate #EoL comm 🗣️
🔗: esmoopen.com/article/S205...
Why does #overtreatment happen in #oncology?
This article defines the #bias and #heuristic that leads to excessive 🔪☢️💉
Solution? #SuppOnc skills - Delivering #BadNews, compassionate #EoL comm 🗣️
🔗: esmoopen.com/article/S205...
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
Many patients with cancer approaching the end of life (EOL) continue to receive treatments
that are unlikely to provide meaningful clinical benefit, potentially causing more
harm than good. This is ca...
esmoopen.com
January 23, 2025 at 10:18 PM
This article explores the social, psychological & cognitive factors contributing to overtreatment at the #EOL and strategies to address them. @oncoalert.bsky.social
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
Final OS analysis from #FALCON:
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
January 19, 2025 at 1:24 PM
Final OS analysis from #FALCON:
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
✅ No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ #ABC
✅ 15% ⬇️ risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months)
@oncoalert.bsky.social
ascopubs.org/doi/full/10.12…
🆕 data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early #BreastCancer with residual disease after neoadjuvant therapy.
7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab)
7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab)
@oncoalert.bsky.social
nejm.org/doi/full/10.10…
7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab)
7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab)
@oncoalert.bsky.social
nejm.org/doi/full/10.10…
January 19, 2025 at 11:04 AM
🆕 data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early #BreastCancer with residual disease after neoadjuvant therapy.
7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab)
7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab)
@oncoalert.bsky.social
nejm.org/doi/full/10.10…
7-year IDFS: 80.8% (T-DM1) 🆚 67.1% (trastuzumab)
7-year OS: 89.1% (T-DM1) 🆚 84.4% (trastuzumab)
@oncoalert.bsky.social
nejm.org/doi/full/10.10…
On January 17, 2025🚨FDA approved☑️datopotamab deruxtecan-dlnk for unresectable/ metastatic, HR-positive, HER2-negative #BreastCancer 🎀who have received prior endocrine and chemotherapy for unresectable/metastatic disease. 🍀 #Oncology #FDAapproval
@oncoalert.bsky.social
www.fda.gov/drugs/resour...
@oncoalert.bsky.social
www.fda.gov/drugs/resour...
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...
www.fda.gov
January 18, 2025 at 4:40 PM
On January 17, 2025🚨FDA approved☑️datopotamab deruxtecan-dlnk for unresectable/ metastatic, HR-positive, HER2-negative #BreastCancer 🎀who have received prior endocrine and chemotherapy for unresectable/metastatic disease. 🍀 #Oncology #FDAapproval
@oncoalert.bsky.social
www.fda.gov/drugs/resour...
@oncoalert.bsky.social
www.fda.gov/drugs/resour...
Intratumoral💉#pembrolizumab & mRNA-2752 for high-risk #DCIS : Phase 1 nonrandomized trial
✅80% response rate
❌no major systemic toxicities
✅ complete tumor resolution in some➡️possible surgery reduction
🎀 ongoing studies needed
@oncoalert.bsky.social
@jama.com
shorturl.at/W7pU2
✅80% response rate
❌no major systemic toxicities
✅ complete tumor resolution in some➡️possible surgery reduction
🎀 ongoing studies needed
@oncoalert.bsky.social
@jama.com
shorturl.at/W7pU2
January 18, 2025 at 4:23 PM
Intratumoral💉#pembrolizumab & mRNA-2752 for high-risk #DCIS : Phase 1 nonrandomized trial
✅80% response rate
❌no major systemic toxicities
✅ complete tumor resolution in some➡️possible surgery reduction
🎀 ongoing studies needed
@oncoalert.bsky.social
@jama.com
shorturl.at/W7pU2
✅80% response rate
❌no major systemic toxicities
✅ complete tumor resolution in some➡️possible surgery reduction
🎀 ongoing studies needed
@oncoalert.bsky.social
@jama.com
shorturl.at/W7pU2
Review of🔑clinical trials in #CRC in 2024
KRYSTAL-1: Adagrasib + cetuximab approved as 1⃣st KRAS G12C therapy for mCRC
TransMet: survival benefits after liver transplant in liver-only mCRC
NICHE-2: 95% major pathologic response with nivolumab + ipilimumab in dMMR colon cancer
@oncoalert.bsky.social
KRYSTAL-1: Adagrasib + cetuximab approved as 1⃣st KRAS G12C therapy for mCRC
TransMet: survival benefits after liver transplant in liver-only mCRC
NICHE-2: 95% major pathologic response with nivolumab + ipilimumab in dMMR colon cancer
@oncoalert.bsky.social
#GIonc summary
top 3 trials in #crcsm
🥇: NICHE-2 - 99% #ORR, 100% 3-year DFS in dMMR colon cancer with ⬇️ #tox
🥈: KRYSTAL-1 - adagrasib in KRAS G12C cancers ➡️ FDA approval + cetux
🥉: TransMet - transplant + 💉 improves 5y #OS
🔗: nature.com/articles/s41...
top 3 trials in #crcsm
🥇: NICHE-2 - 99% #ORR, 100% 3-year DFS in dMMR colon cancer with ⬇️ #tox
🥈: KRYSTAL-1 - adagrasib in KRAS G12C cancers ➡️ FDA approval + cetux
🥉: TransMet - transplant + 💉 improves 5y #OS
🔗: nature.com/articles/s41...
Moving towards more personalized approaches in locally advanced and metastatic colorectal cancer - Nature Reviews Gastroenterology & Hepatology
Colorectal cancer remains a challenging heterogeneous disease with substantial morbidity and mortality. However, progressive advances over the past year have led to marked improvements and overcome ch...
nature.com
January 18, 2025 at 4:21 PM
Review of🔑clinical trials in #CRC in 2024
KRYSTAL-1: Adagrasib + cetuximab approved as 1⃣st KRAS G12C therapy for mCRC
TransMet: survival benefits after liver transplant in liver-only mCRC
NICHE-2: 95% major pathologic response with nivolumab + ipilimumab in dMMR colon cancer
@oncoalert.bsky.social
KRYSTAL-1: Adagrasib + cetuximab approved as 1⃣st KRAS G12C therapy for mCRC
TransMet: survival benefits after liver transplant in liver-only mCRC
NICHE-2: 95% major pathologic response with nivolumab + ipilimumab in dMMR colon cancer
@oncoalert.bsky.social
Ultrasensitive ctDNA 🧬detection for pre-op stratification in early LUAD 🫁: Analysis from #TRACERx :
buff.ly/4jl6fLR
🧬NeXT Personal detects #ctDNA in 81% pre-op LUAD 🫁, even in stage I.
🧬ctDNA <80 ppm predicts worse outcomes🆚ctDNA-negative cases.
#LungCancer
buff.ly/4jl6fLR
🧬NeXT Personal detects #ctDNA in 81% pre-op LUAD 🫁, even in stage I.
🧬ctDNA <80 ppm predicts worse outcomes🆚ctDNA-negative cases.
#LungCancer
January 18, 2025 at 4:20 PM
Ultrasensitive ctDNA 🧬detection for pre-op stratification in early LUAD 🫁: Analysis from #TRACERx :
buff.ly/4jl6fLR
🧬NeXT Personal detects #ctDNA in 81% pre-op LUAD 🫁, even in stage I.
🧬ctDNA <80 ppm predicts worse outcomes🆚ctDNA-negative cases.
#LungCancer
buff.ly/4jl6fLR
🧬NeXT Personal detects #ctDNA in 81% pre-op LUAD 🫁, even in stage I.
🧬ctDNA <80 ppm predicts worse outcomes🆚ctDNA-negative cases.
#LungCancer
🫀dysfunction, including heart failure, is a ⬆️concern for #BreastCancerSurvivors due to cardiotoxic therapy like anthracyclines & trastuzumab.
A Korean study shows that
⬆️weight gain after a #BC diagnosis ⬆️ risk of heart failure💔
@oncoalert.bsky.social @jama.com
ja.ma/42eruIO
A Korean study shows that
⬆️weight gain after a #BC diagnosis ⬆️ risk of heart failure💔
@oncoalert.bsky.social @jama.com
ja.ma/42eruIO
Weight Changes and Heart Failure After Breast Cancer
This cohort study assesses the role of postdiagnosis and prediagnosis in weight gain in individuals with higher risk for cardiac dysfunction.
ja.ma
January 14, 2025 at 11:02 PM
🫀dysfunction, including heart failure, is a ⬆️concern for #BreastCancerSurvivors due to cardiotoxic therapy like anthracyclines & trastuzumab.
A Korean study shows that
⬆️weight gain after a #BC diagnosis ⬆️ risk of heart failure💔
@oncoalert.bsky.social @jama.com
ja.ma/42eruIO
A Korean study shows that
⬆️weight gain after a #BC diagnosis ⬆️ risk of heart failure💔
@oncoalert.bsky.social @jama.com
ja.ma/42eruIO
Thrilled to share that after an incredible mentorship experience with Prof. Matteo Lambertini last year, I’ve been selected for the 2025 ESO mentorship program!🌟This year, I have the honor of being mentored by Prof. Bostjan Seruga. 🙌
Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social
Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social
January 14, 2025 at 9:13 PM
Thrilled to share that after an incredible mentorship experience with Prof. Matteo Lambertini last year, I’ve been selected for the 2025 ESO mentorship program!🌟This year, I have the honor of being mentored by Prof. Bostjan Seruga. 🙌
Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social
Excited for the journey ahead! 😊😊😊 @oncoalert.bsky.social
🌟 #Supponc systematic review highlights the 🔼 use of #AI 🤖 in symptom prediction & monitoring for adult #CancerSurvivors.
Pain, fatigue & nausea are🔑symptoms monitored with #AI tools like machine learning & NLP, revolutionizing patient care. 🌟
@oncoalert.bsky.social
👉 shorturl.at/vdKKQ
Pain, fatigue & nausea are🔑symptoms monitored with #AI tools like machine learning & NLP, revolutionizing patient care. 🌟
@oncoalert.bsky.social
👉 shorturl.at/vdKKQ
An interesting #supponc review
#AI🤖 in #survonc symptom monitoring
41 studies (2021-2023) ⬆️machine learning and NLP models.
Pain ⚡️🥴 fatigue 🛌😴 and nausea 🤢🤮were 🔑 focus
More trials to optimize integration 🧑⚕️🤝🤖
🔗: ascopubs.org/doi/10.1200/...
#AI🤖 in #survonc symptom monitoring
41 studies (2021-2023) ⬆️machine learning and NLP models.
Pain ⚡️🥴 fatigue 🛌😴 and nausea 🤢🤮were 🔑 focus
More trials to optimize integration 🧑⚕️🤝🤖
🔗: ascopubs.org/doi/10.1200/...
January 14, 2025 at 12:08 AM
🌟 #Supponc systematic review highlights the 🔼 use of #AI 🤖 in symptom prediction & monitoring for adult #CancerSurvivors.
Pain, fatigue & nausea are🔑symptoms monitored with #AI tools like machine learning & NLP, revolutionizing patient care. 🌟
@oncoalert.bsky.social
👉 shorturl.at/vdKKQ
Pain, fatigue & nausea are🔑symptoms monitored with #AI tools like machine learning & NLP, revolutionizing patient care. 🌟
@oncoalert.bsky.social
👉 shorturl.at/vdKKQ
🌟Exploring neoadjuvant therapy for occult #BreastCancer with axillary presentation, a retrospective study of 114 patients suggests that targeted axillary surgery may be considered instead of axillary dissection in select cases. 🌟
Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF
Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF
Shifting from axillary dissection to targeted axillary surgery after neoadj tx
https://buff.ly/3Wfs9WI
Study explored the role of neoadjuvant systemic therapy in managing occult #BreastCancer w/ axillary presentation, which can enable less invasive surgical treatments.
https://buff.ly/3Wfs9WI
Study explored the role of neoadjuvant systemic therapy in managing occult #BreastCancer w/ axillary presentation, which can enable less invasive surgical treatments.
January 13, 2025 at 7:22 PM
🌟Exploring neoadjuvant therapy for occult #BreastCancer with axillary presentation, a retrospective study of 114 patients suggests that targeted axillary surgery may be considered instead of axillary dissection in select cases. 🌟
Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF
Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF
Eribulin combined with trastuzumab & pertuzumab shows potential to become the🆕standard in 1️⃣st-line treatment for HER2+ locally advanced/metastatic #BreastCancer. Results from the phase III EMERALD trial suggest comparable efficacy to taxanes, with improved QoL.
👉 buff.ly/4hfnuMJ
👉 buff.ly/4hfnuMJ
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer:EMERALD Trial
https://buff.ly/4hfnuMJ
Results suggest eribulin + HP is a viable first-line option for HER2+ breast cancer.
https://buff.ly/4hfnuMJ
Results suggest eribulin + HP is a viable first-line option for HER2+ breast cancer.
January 13, 2025 at 7:20 PM
Eribulin combined with trastuzumab & pertuzumab shows potential to become the🆕standard in 1️⃣st-line treatment for HER2+ locally advanced/metastatic #BreastCancer. Results from the phase III EMERALD trial suggest comparable efficacy to taxanes, with improved QoL.
👉 buff.ly/4hfnuMJ
👉 buff.ly/4hfnuMJ
Study of 542,778 women in the UK (16.6 yrs, 12,251 cases) links diet to #ColorectalCancer risk:
🔺 Higher risk: 🍷Alcohol &🥩 Red/processed meat
🔻 Protective:
🥛 Dairy (calcium)
🌾 Wholegrains & fiber
🍎 Fruits &🍳Cereal
🍋 Vitamin C &🥬Folate
🍚 Carbs
Read more 👉 buff.ly/40eEVGd
@oncoalert.bsky.social
🔺 Higher risk: 🍷Alcohol &🥩 Red/processed meat
🔻 Protective:
🥛 Dairy (calcium)
🌾 Wholegrains & fiber
🍎 Fruits &🍳Cereal
🍋 Vitamin C &🥬Folate
🍚 Carbs
Read more 👉 buff.ly/40eEVGd
@oncoalert.bsky.social
January 13, 2025 at 7:19 PM
Study of 542,778 women in the UK (16.6 yrs, 12,251 cases) links diet to #ColorectalCancer risk:
🔺 Higher risk: 🍷Alcohol &🥩 Red/processed meat
🔻 Protective:
🥛 Dairy (calcium)
🌾 Wholegrains & fiber
🍎 Fruits &🍳Cereal
🍋 Vitamin C &🥬Folate
🍚 Carbs
Read more 👉 buff.ly/40eEVGd
@oncoalert.bsky.social
🔺 Higher risk: 🍷Alcohol &🥩 Red/processed meat
🔻 Protective:
🥛 Dairy (calcium)
🌾 Wholegrains & fiber
🍎 Fruits &🍳Cereal
🍋 Vitamin C &🥬Folate
🍚 Carbs
Read more 👉 buff.ly/40eEVGd
@oncoalert.bsky.social
🌟EMERALD: Eribulin + HP is an option for 1️⃣st-line treatment of locally advanced/metastatic HER2+ #BreastCancer :
✅ Noninferior efficacy to taxane
✅Toxicity differences:
⬇️ infusion reactions, diarrhea, and edema
⬆️ neutropenia
@oncoalert.bsky.social @JCO_ASCO
ascopubs.org/doi/10.1200/...
✅ Noninferior efficacy to taxane
✅Toxicity differences:
⬇️ infusion reactions, diarrhea, and edema
⬆️ neutropenia
@oncoalert.bsky.social @JCO_ASCO
ascopubs.org/doi/10.1200/...
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase II...
PURPOSETrastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for
recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC).
We investigated noninfer...
ascopubs.org
January 11, 2025 at 10:07 AM
🌟EMERALD: Eribulin + HP is an option for 1️⃣st-line treatment of locally advanced/metastatic HER2+ #BreastCancer :
✅ Noninferior efficacy to taxane
✅Toxicity differences:
⬇️ infusion reactions, diarrhea, and edema
⬆️ neutropenia
@oncoalert.bsky.social @JCO_ASCO
ascopubs.org/doi/10.1200/...
✅ Noninferior efficacy to taxane
✅Toxicity differences:
⬇️ infusion reactions, diarrhea, and edema
⬆️ neutropenia
@oncoalert.bsky.social @JCO_ASCO
ascopubs.org/doi/10.1200/...
Dear colleagues,
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈
📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology
Don’t miss this unique #oncology event! 🌍👩⚕️👨⚕️
@oncoalert.bsky.social #OncoAlertAF
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈
📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology
Don’t miss this unique #oncology event! 🌍👩⚕️👨⚕️
@oncoalert.bsky.social #OncoAlertAF
January 10, 2025 at 6:31 PM
Dear colleagues,
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈
📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology
Don’t miss this unique #oncology event! 🌍👩⚕️👨⚕️
@oncoalert.bsky.social #OncoAlertAF
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈
📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology
Don’t miss this unique #oncology event! 🌍👩⚕️👨⚕️
@oncoalert.bsky.social #OncoAlertAF
✨AMBASSADOR✨: Adjuvant #Pembrolizumab🆚 Observation in Muscle-Invasive Urothelial Carcinoma
🕒FU: Median 44.8 months
📈DFS: 29.6 months (Pembro) 🆚 14.2 months (Obs) HR 0.73 (p=0.003)
⚠️AEs G≥3: 50.6% (Pembro) vs 31.6% (Obs)
@oncoalert.bsky.social @nejm.org
👉 www.nejm.org/doi/full/10....
🕒FU: Median 44.8 months
📈DFS: 29.6 months (Pembro) 🆚 14.2 months (Obs) HR 0.73 (p=0.003)
⚠️AEs G≥3: 50.6% (Pembro) vs 31.6% (Obs)
@oncoalert.bsky.social @nejm.org
👉 www.nejm.org/doi/full/10....
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse.
Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk
muscle-invasive uro...
www.nejm.org
January 9, 2025 at 11:25 PM
✨AMBASSADOR✨: Adjuvant #Pembrolizumab🆚 Observation in Muscle-Invasive Urothelial Carcinoma
🕒FU: Median 44.8 months
📈DFS: 29.6 months (Pembro) 🆚 14.2 months (Obs) HR 0.73 (p=0.003)
⚠️AEs G≥3: 50.6% (Pembro) vs 31.6% (Obs)
@oncoalert.bsky.social @nejm.org
👉 www.nejm.org/doi/full/10....
🕒FU: Median 44.8 months
📈DFS: 29.6 months (Pembro) 🆚 14.2 months (Obs) HR 0.73 (p=0.003)
⚠️AEs G≥3: 50.6% (Pembro) vs 31.6% (Obs)
@oncoalert.bsky.social @nejm.org
👉 www.nejm.org/doi/full/10....
⏳Delayed nephrectomy in #mRCC pts with CR/mPR after #immunotherapy shows🍀promising outcomes (48% progression-free at 29.6 months) but comes with ⬆️ surgical complexity - 65.7% cases faced challenges when tumor downsizing >10%.
👉 link.springer.com/article/10.1...
@oncoalert.bsky.social #OncoAlertAF
👉 link.springer.com/article/10.1...
@oncoalert.bsky.social #OncoAlertAF
January 9, 2025 at 10:33 PM
⏳Delayed nephrectomy in #mRCC pts with CR/mPR after #immunotherapy shows🍀promising outcomes (48% progression-free at 29.6 months) but comes with ⬆️ surgical complexity - 65.7% cases faced challenges when tumor downsizing >10%.
👉 link.springer.com/article/10.1...
@oncoalert.bsky.social #OncoAlertAF
👉 link.springer.com/article/10.1...
@oncoalert.bsky.social #OncoAlertAF
🚨The @oncoalert.bsky.social Video Journal 🚨
🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer
🎥 Watch the highlights 👇
🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer
🎥 Watch the highlights 👇
The OncoAlert Video Journal: "Deep Learning Model for Predicting Immunotherapy Response in Advanced #NSCLC Non−Small Cell #LungCancer 🫁"
This Week @biagioricciutimd.bsky.social 🇺🇸of @danafarbernews.bsky.social Guides us through his paper out on JAMA oncology
www.youtube.com/watch?v=LuD4...
This Week @biagioricciutimd.bsky.social 🇺🇸of @danafarbernews.bsky.social Guides us through his paper out on JAMA oncology
www.youtube.com/watch?v=LuD4...
OncoAlert Video Journal: Dr.Ricciuti/Deep Learning Model for Predicting IO ResponseNSCLC Lung Cancer
YouTube video by OncoAlert 360
www.youtube.com
January 8, 2025 at 2:29 PM
🚨The @oncoalert.bsky.social Video Journal 🚨
🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer
🎥 Watch the highlights 👇
🌟This week, our #OncoAlertAF colleague @biagioricciutimd.bsky.social guides us through his paper in @jama.com:Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer
🎥 Watch the highlights 👇
💡CMG901, the 1️⃣st #ADC targeting Claudin 18.2, demonstrated promising antitumor activity in a phase 1 trial in patients with advanced #gastric and #GEJ cancers:
⚠️Common AEs were vomiting, anorexia, proteinuria, anemia (Gr ≥3 in 68%)
Read more: buff.ly/3PmhYfk
⚠️Common AEs were vomiting, anorexia, proteinuria, anemia (Gr ≥3 in 68%)
Read more: buff.ly/3PmhYfk
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901)
2.2 mg/kg was proposed as the recommended phase 2 dose, & CMG901 demonstrated a manageable safety profile with promising antitumor activity
https://buff.ly/3PmhYfk
2.2 mg/kg was proposed as the recommended phase 2 dose, & CMG901 demonstrated a manageable safety profile with promising antitumor activity
https://buff.ly/3PmhYfk
January 7, 2025 at 7:21 PM
💡CMG901, the 1️⃣st #ADC targeting Claudin 18.2, demonstrated promising antitumor activity in a phase 1 trial in patients with advanced #gastric and #GEJ cancers:
⚠️Common AEs were vomiting, anorexia, proteinuria, anemia (Gr ≥3 in 68%)
Read more: buff.ly/3PmhYfk
⚠️Common AEs were vomiting, anorexia, proteinuria, anemia (Gr ≥3 in 68%)
Read more: buff.ly/3PmhYfk
💡Great overview of the role of #immunotherapy in advanced #LUSC 🫁and the remaining questions: optimizing regimens, identifying robust biomarkers, and exploring emerging strategies like💉next-generation ICIs, bispecific antibodies and personalized vaccines.
#Oncology
#Oncology
Immunotherapy for advanced-stage squamous cell #LungCancer : the state of the art and outstanding questions
Novel therapies, including next-generation ICIs, bispecific antibodies, and personalized cancer vaccines, are emerging as potential advances in LUSC treatment.
https://buff.ly/4aeBeFe
Novel therapies, including next-generation ICIs, bispecific antibodies, and personalized cancer vaccines, are emerging as potential advances in LUSC treatment.
https://buff.ly/4aeBeFe
January 7, 2025 at 7:20 PM
💡Great overview of the role of #immunotherapy in advanced #LUSC 🫁and the remaining questions: optimizing regimens, identifying robust biomarkers, and exploring emerging strategies like💉next-generation ICIs, bispecific antibodies and personalized vaccines.
#Oncology
#Oncology
🌟Study of 257 Finnish #BreastCancer pts identified🔑predictive factors for response to neoadjuvant therapy. @springernature.bsky.social
Key findings:
⚠️⬇️ PR = 3.8x⬆️mortality risk
Personalized, risk-adapted surveillance & treatment is crucial!
@oncoalert.bsky.social
link.springer.com/article/10.1...
Key findings:
⚠️⬇️ PR = 3.8x⬆️mortality risk
Personalized, risk-adapted surveillance & treatment is crucial!
@oncoalert.bsky.social
link.springer.com/article/10.1...
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma - Breast Cancer Research and Treatment
Purpose Due to biological heterogeneity of breast carcinoma, predicting the individual response to neoadjuvant treatment (NAT) is complex. Consequently, there are no comprehensive, generally accepted ...
link.springer.com
January 7, 2025 at 12:18 AM
🌟Study of 257 Finnish #BreastCancer pts identified🔑predictive factors for response to neoadjuvant therapy. @springernature.bsky.social
Key findings:
⚠️⬇️ PR = 3.8x⬆️mortality risk
Personalized, risk-adapted surveillance & treatment is crucial!
@oncoalert.bsky.social
link.springer.com/article/10.1...
Key findings:
⚠️⬇️ PR = 3.8x⬆️mortality risk
Personalized, risk-adapted surveillance & treatment is crucial!
@oncoalert.bsky.social
link.springer.com/article/10.1...